Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs KYMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KYMR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

KYMR Overall Winner 6-Pillar Tally: IONS 3 – 3 KYMR Matrix Metrics: IONS 4 – 6 KYMR

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas KYMR carries 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. -58.8% operating margin) and revenue trajectory (+466.4% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs KYMR
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
KYMR NASDAQ Head-to-Head Winner
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
TTM Revenue $102M
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 52
RSI-14: 51.7 · SMA20: $124.62 · SMA50: $117.28

6-Pillar Scorecard Institutional Category Breakdown (IONS 3 – 3 KYMR)

Columns: Metric · IONS · KYMR
1. Valuation Multiples IONS
Forward P/E 90.9x N/M
Trailing P/E 90.9x N/M
PEG Ratio N/M N/M
EV / Revenue 6.2x 103.3x
2. Growth & Scale KYMR
Revenue Growth (YoY) +54.9% +466.4%
Earnings Growth (YoY) -43.7% +0.0%
TTM Revenue (USD) $960M $102M
Market Cap $4.7B $10.9B
3. Profitability & Quality IONS
Gross Margin 3.0% N/A
Operating Margin -58.8% -396.0%
Net Profit Margin -56.9% 0.0%
Return on Equity (ROE) -108.0% -27.3%
4. Balance Sheet & Cash Flow KYMR
Cash Generation (TTM) -$623M -$289M
Cash Flow Margin -64.9% N/A
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $297M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KYMR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 59.9% (17th %ile) 129.6% (23rd %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (4) vs KYMR (6)
Institutional Metric IONS KYMR Criterion Row Edge
Market Capitalization
Scale
$4.7B $10.9B Larger Scale KYMR
Trailing P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Forward P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Revenue Growth (YoY)
Growth
+54.9% +466.4% Higher Growth KYMR
Operating Margin (TTM)
Profitability
-58.8% -396.0% Higher Margin IONS
Net Profit Margin
Profitability
-56.9% 0.0% Higher Margin KYMR
Return on Equity (ROE)
Capital Efficiency
-108.0% -27.3% Higher ROE KYMR
52-Week Range Position
Momentum
2% ($27–$87) 78% ($62–$143) Stronger Trend KYMR
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.04β · 54% Vol Lower Realized Risk KYMR
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 47.1 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $102M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 103.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$289M ($297M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KYMR +52.58 pp
IONS: -33.48% · KYMR: +19.1%
3M Horizon KYMR +54.9 pp
IONS: -52.09% · KYMR: +2.81%
6M Horizon KYMR +117.24 pp
IONS: -60.61% · KYMR: +56.63%
1Y Horizon KYMR +155.22 pp
IONS: -59.1% · KYMR: +96.12%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue KYMR Revenue IONS Op. Margin KYMR Op. Margin Margin Leader
FY2018 $600M N/A -10.2% N/A IONS
FY2019 $1.12B $0M 32.6% -1438.5% IONS
FY2020 $730M $30M -23.6% -136.1% IONS
FY2021 $810M $70M -3.7% -138.0% IONS
FY2022 $590M $50M -69.8% -344.4% IONS
FY2023 $790M $80M -44.9% -210.6% IONS
FY2024 $710M $50M -67.4% -555.8% IONS
FY2025 $940M $40M -40.4% -891.1% IONS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KYMR CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 129.6%
IV Percentile 23rd %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KYMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
KYMR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.9B market capitalization and -396.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs KYMR Key Questions & Quantitative Answers

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas KYMR carries 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. -58.8% operating margin) and revenue trajectory (+466.4% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KYMR leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with KYMR at +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while KYMR shifted +33.3%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KYMR.

IONS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus KYMR (-27.3% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.